Which drug class is described as 'awesome' in heart failure therapy?

Which drug class is described as 'awesome' in heart failure therapy?

• A. Beta blockers
• B. ACE inhibitors
• C. SGLT2 inhibitors
• D. Diuretics

Answer: (C)

In heart failure therapy, SGLT2 inhibitors stand out because they improve outcomes beyond just lowering blood sugar. Large trials have shown they reduce heart-failure hospitalizations and cardiovascular death in patients with reduced ejection fraction and, more recently, have demonstrated benefits in preserved ejection fraction too, including in people without diabetes. This broad benefit makes them a standout addition to standard HF regimens. The reasons include multiple mechanisms working together: they promote osmotic diuresis and natriuresis, which help unload the heart and relieve congestion; they provide kidney-protective effects that slow progression of kidney disease, a major factor in heart failure outcomes; and they may improve myocardial energetics by shifting metabolism toward more efficient fuel use. There are also anti-inflammatory and anti-fibrotic effects that help prevent adverse cardiac remodeling. Taken with other HF drugs—beta-blockers, ARNI or ACE inhibitors, and MRAs—these agents add a powerful, complementary layer of benefit. Side effects are generally manageable, with attention to volume status and potential risks like genital infections or rare ketoacidosis.

In heart failure therapy, SGLT2 inhibitors stand out because they improve outcomes beyond just lowering blood sugar. Large trials have shown they reduce heart-failure hospitalizations and cardiovascular death in patients with reduced ejection fraction and, more recently, have demonstrated benefits in preserved ejection fraction too, including in people without diabetes. This broad benefit makes them a standout addition to standard HF regimens.

The reasons include multiple mechanisms working together: they promote osmotic diuresis and natriuresis, which help unload the heart and relieve congestion; they provide kidney-protective effects that slow progression of kidney disease, a major factor in heart failure outcomes; and they may improve myocardial energetics by shifting metabolism toward more efficient fuel use. There are also anti-inflammatory and anti-fibrotic effects that help prevent adverse cardiac remodeling. Taken with other HF drugs—beta-blockers, ARNI or ACE inhibitors, and MRAs—these agents add a powerful, complementary layer of benefit. Side effects are generally manageable, with attention to volume status and potential risks like genital infections or rare ketoacidosis.